A Review of Anti-HER2 Targeted Agents in Non-Breast Solid Tumors
This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.
Stay updated with breaking news from Profiling Utilization Registry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.
Our roundup of the latest news from metro Detroit and Michigan businesses as well as announcements from government agencies.
email article After close to a decade at the helm, Richard Schilsky, MD, has retired from his role as chief medical officer of the American Society of Clinical Oncology (ASCO). His legacy as the organization's first CMO will be what he calls the "ASCO research enterprise" -- launching ASCO's first-ever clinical trial, increasing its ability to conduct observational studies, and tapping into the 40,000-person membership for original survey-based research. "It was clear that while ASCO was a tremendous vehicle to disseminate and amplify research findings that were generated by various e...
Speakers: Monica M. Bertagnolli, MD, FACS, FASCO, President and Chair of the Board, American Society of Clinical Oncology Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology Oliver Bogler, PhD, Chief Operating Officer, ECHO Institute™ Leslie Byatt, CPhT, CCRC, Clinical Research Manager, New Mexico Cancer Care Alliance, New Mexico Cancer Care Alliance Robert T. Croyle, PhD, Director, Division of Cancer Control and Population Sciences, National Cancer Institute Hedvig Hricak, MD, PhD, Chair, Department of Ra...